

CURRICULUM VITAE

Professor Daniel Palmer, Professor of Molecular and Clinical Cancer Medicine

EMPLOYMENT HISTORY

2011-present North West Cancer Research Professor of Medical Oncology, University of Liverpool and Honorary Consultant in Medical Oncology, Clatterbridge Cancer Centre
Oct 2010 - Mar 2011 Senior Lecturer in Medical Oncology, University of Birmingham
Sept 2005- Sept 2010 Cancer Research UK Clinician Scientist, University of Birmingham

HIGHER EDUCATION AND OTHER QUALIFICATIONS

2004 Ph.D Cancer Studies, University of Birmingham
1998 MRCP, Royal College of Physicians of London
1995 MBChB, University of Birmingham
1994 BSc (Hons) Pathological Studies (1st Class), University of Birmingham

AWARDS AND POSITIONS OF TRUST

Director, Liverpool CR UK/NIHR Experimental Cancer Medicine Centre
Head of Section of Medical Oncology, University of Liverpool
Deputy Director, Liverpool CR UK Clinical Trials Unit
Member NCRI Upper GI Cancers Clinical Studies Group
Member NCRI Pancreas Cancer Subgroup
Member NCRI Hepatobiliary Cancers Subgroup
Member American Society of Clinical Oncology
Association of Cancer Physicians McElwain Scholarship, 2005
Expert testimony for Pancreatic and Hepatobiliary Cancer Cases

RECENT GRANTS

2019 – 2024 Astra Zeneca. Arachnid: A platform study of immunotherapy in combination with different radiotherapy modalities for patients with advanced hepatocellular carcinoma. £1,000,000. (PI)
2017 – 2022 BMS TACE-3: A Randomised Phase II/III clinical trial of TACE +/- nivolumab in patients with intermediate stage hepatocellular carcinoma. £4,083,253. (PI)
2017 – 2022 CRUK/NIHR Liverpool Experimental Cancer Medicine Centre. £1,500,000. (PI)
2015 – 2019 A20220: ACELARATE - A Phase III, open label, multicentre randomized clinical trial comparing Acelarin with Gemcitabine in patients with metastatic pancreatic adenocarcinoma. CRUKE/15/013. £1,390,000 (PI) Funding Nucana; CTAAC endorsed).
2017-2020 CRUK Multi-disciplinary Research Award: Development of nano-medicines. £430,000 Palmer DH and Rannard S (Co-PI)
2014 – 2016 North West Cancer Research Fund A clinical trial of neo-adjuvant chemotherapy for borderline resectable biliary cancer £119,657 (PI)
2011 – 2016 North West Cancer Research Fund Academic Medical Oncology Core Funding. £1,000,000 (PI)
2012 – 2013 North West Cancer Research Fund Applied Cancer Biology Core Funding. £170,000 (PI)
2013 – 2014 Clatterbridge Cancer Centre Charitable Trust. Novel biomarkers of chemotherapy-induced liver injury. £20,000 (PI)

SELECTED RECENT PUBLICATIONS

1. Valle JW, Wasan H, Lopes A, Backen AC, **Palmer DH**, Morris K, Duggan M, Cunningham D, Anthoney DA, Corrie P, Madhusudan S, Maraveyas A, Ross PJ, Waters JS, Steward WP, Rees C, Beare S, Dive C, Bridgewater JA. Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): a randomised phase 2 trial. *Lancet Oncol.* 2015;16(8):967-78
2. Nielsen SR, Quaranta V, Linford A, Emeagi P, Rainer C, Santos A, Ireland L, Sakai T, Sakai K, Kim YS, Engle D, Campbell F, **Palmer D**, Ko JH, Tuveson DA, Hirsch E, Mielgo A, Schmid MC. Macrophage-secreted granulin supports pancreatic cancer metastasis by inducing liver fibrosis. *Nat Cell Biol.* 2016 May;18(5):549-60.
3. Connor AA, Denroche RE, Jang GH, Timms L, Kalimuthu SN, Selander I, McPherson T, Wilson GW, Chan-Seng-Yue MA, Borozan I, Ferretti V, Grant RC, Lungu IM, Costello E, Greenhalf W, **Palmer D**, Ghaneh P, Neoptolemos JP, Buchler M, Petersen G, Thayer S, Hollingsworth MA, Sherker A, Durocher D, Dhani N, Hedley D, Serra S, Pollett A, Roehrl MH, Bavi P, Bartlett JM, Cleary S, Wilson JM, Alexandrov LB, Moore M, Wouters BG, McPherson JD, Notta F, Stein LD, Gallinger S. Association of Distinct Mutational Signatures With Correlates of Increased Immune Activity in Pancreatic Ductal Adenocarcinoma. *JAMA Oncol.* 2016 Oct 20.
4. Neoptolemos JP, **Palmer DH**, Ghaneh P, Psarelli EE, Valle JW, Halloran CM, Faluyi O, O'Reilly DA, Cunningham D, Wadsley J, Darby S, Meyer T, Gillmore R, Anthoney A, Lind P, Glimelius B, Falk S, Izbicki JR, Middleton GW, Cummins S, Ross PJ, Wasan H, McDonald A, Crosby T, Ma YT, Patel K, Sherriff D, Soomal R, Borg D, Sothi S, Hammel P, Hackert T, Jackson R, Büchler MW; European Study Group for Pancreatic Cancer.. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. *Lancet.* 2017 Jan 24. pii:S0140-6736(16)32409-6.
5. Bird NT, Elmasry M, Jones R, Psarelli E, Dodd J, Malik H, Greenhalf W, Kitteringham N, Ghaneh P, Neoptolemos JP, **Palmer D**. Immunohistochemical hENT1 expression as a prognostic biomarker in patients with resected pancreatic ductal adenocarcinoma undergoing adjuvant gemcitabine-based chemotherapy. *Br J Surg.* 2017 Mar;104(4):328-336.
6. Middleton G, **Palmer DH**, Greenhalf W, Ghaneh P, Jackson R, Cox T, Evans A, Shaw VE, Wadsley J, Valle JW, Propper D, Wasan H, Falk S, Cunningham D, Coxon F, Ross P, Madhusudan S, Wadd N, Corrie P, Hickish T, Costello E, Campbell F, Rawcliffe C, Neoptolemos JP. Vandetanib plus gemcitabine versus placebo plus gemcitabine in locally advanced or metastatic pancreatic carcinoma (ViP): a prospective, randomised, double-blind, multicentre phase 2 trial. *Lancet Oncol.* 2017 Mar 1. pii: S1470-2045(17)30084-0.
7. Totti S, Vernardis SI, Meira L, Pérez-Mancera PA, Costello E, Greenhalf W, **Palmer D**, Neoptolemos J, Mantalaris A, Velliou EG. Designing a bio inspired biomimetic in vitro system for the optimization of ex vivo studies of pancreatic cancer. *Drug Discov Today.* 2017;22(4):690-701
8. Psarelli EE, Jackson R, Neoptolemos JP, **Palmer DH**, Ghaneh P, Halloran CM, Büchler MW. Beyond ESPAC-4: better surgery and systemic therapy. *Lancet.* 2017;389(10078):1517-1518
9. Meyer T, Fox R, Ma YT, Ross PJ, James MW, Sturgess R, Stubbs C, Stocken DD, Wall L, Watkinson A, Hacking N, Evans TRJ, Collins P, Hubner RA, Cunningham D, Primrose JN, Johnson PJ, **Palmer DH**. Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial. *Lancet Gastroenterol Hepatol.* 2017;2(8):565-575
10. Ma YT, Leonard SM, Gordon N, Anderton J, James C, Huen D, Woodman CB, **Palmer DH**. Use of a genome-wide haploid genetic screen to identify treatment predicting factors: a proof-of-principle study in pancreatic cancer. *Oncotarget.* 2017;8(38):63635-63645
11. Neoptolemos JP, Kleeff J, Michl P, Costello E, Greenhalf W, **Palmer DH**. Therapeutic developments in pancreatic cancer: breaking through. *Nature Reviews Gastroenterology and Hepatology*, 2018 *In press*.
12. Evans JP, Winiarski BK, Sutton PA, Jones RP, Ressel L, Duckworth CA, Pritchard DM, Lin

- ZX, Fretwell VL, Tweedle EM, Costello E, Goldring CE, Copple IM, Park BK, Palmer DH, Kitteringham NR. Correction: The Nrf2 inhibitor brusatol is a potent antitumour agent in an orthotopic mouse model of colorectal cancer. *Oncotarget*. 2019 Jan 18;10(6):685.
13. Evans JP, Winiarski BK, Sutton PA, Ressel L, Duckworth CA, Pritchard DM, Palmer DH, Goldring CE, Kitteringham NR. Development of an orthotopic syngeneic murine model of colorectal cancer for use in translational research. *Lab Anim*. 2019 Feb 13:23677219826165.
 14. Javed MA, Beyer G, Le N, Vinci A, Wong H, Palmer D, Morgan RD, Lamarca A, Hubner RA, Valle JW, Alam S, Chowdhury S, Ma YT, Archibugi L, Capurso G, Maisonneuve P, Neesse A, Sund M, Schober M, Krug S. Impact of intensified chemotherapy in metastatic pancreatic ductal adenocarcinoma (PDAC) in clinical routine in Europe. *Pancreatol*. 2019 Jan;19(1):97-104.
 15. Mahajan UM, Langhoff E, Goni E, Costello E, Greenhalf W, Halloran C, Ormanns S, Kruger S, Boeck S, Ribback S, Beyer G, Dombrowski F, Weiss FU, Neoptolemos JP, Werner J, D'Haese JG, Bazhin A, Peterhansl J, Pichlmeier S, Büchler MW, Kleeff J, Ganeh P, Sendler M, Palmer DH, Kohlmann T, Rad R, Regel I, Lerch MM, Mayerle J. Immune Cell and Stromal Signature Associated With Progression-Free Survival of Patients With Resected Pancreatic Ductal Adenocarcinoma. *Gastroenterology*. 2018 Nov;155(5):1625-1639.e2.
 16. Backen AC, Lopes A, Wasan H, Palmer DH, Duggan M, Cunningham D, Anthony A, Corrie PG, Madhusudan S, Maraveyas A, Ross PJ, Waters JS, Steward WP, Rees C, McNamara MG, Beare S, Bridgewater JA, Dive C, Valle JW. Circulating biomarkers during treatment in patients with advanced biliary tract cancer receiving cediranib in the UK ABC-03 trial. *Br J Cancer*. 2018 Jul;119(1):27-35.
 17. Zhu AX, Finn RS, Edeline J, Cattani S, Ogasawara S, Palmer D, Verslype C, Zagonel V, Fartoux L, Vogel A, Sarker D, Verset G, Chan SL, Knox J, Daniele B, Webber AL, Ebbinghaus SW, Ma J, Siegel AB, Cheng AL, Kudo M; KEYNOTE-224 investigators. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. *Lancet Oncol*. 2018 Jul;19(7):940-952.
 18. Quaranta V, Rainer C, Nielsen SR, Raymant ML, Ahmed MS, Engle DD, Taylor A, Murray T, Campbell F, Palmer DH, Tuveson DA, Mielgo A, Schmid MC. Macrophage-Derived Granulin Drives Resistance to Immune Checkpoint Inhibition in Metastatic Pancreatic Cancer. *Cancer Res*. 2018 Aug 1;78(15):4253-4269.
 19. Neoptolemos JP, Kleeff J, Michl P, Costello E, Greenhalf W, Palmer DH. Therapeutic developments in pancreatic cancer: current and future perspectives. *Nat Rev Gastroenterol Hepatol*. 2018 Jun;15(6):333-348.
 20. Stainthorpe A, Greenhalgh J, Bagust A, Richardson M, Boland A, Beale S, Duarte R, Kotas E, Banks L, Palmer D. Paclitaxel as Albumin-Bound Nanoparticles with Gemcitabine for Untreated Metastatic Pancreatic Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. *Pharmacoeconomics*. 2018 Oct;36(10):1153-1163.
 21. Palmer DH, Ma YT, Peck-Radosavljevic M, Ross P, Graham J, Fartoux L, Deptala A, Studeny M, Schnell D, Hocke J, Loembé AB, Meyer T. A multicentre, open-label, phase-I/randomised phase-II study to evaluate safety, pharmacokinetics, and efficacy of nintedanib vs. sorafenib in European patients with advanced hepatocellular carcinoma. *Br J Cancer*. 2018 May;118(9):1162-1168.
 22. Elander NO, Aughton K, Ghaneh P, Neoptolemos JP, Palmer DH, Cox TF, Campbell F, Costello E, Halloran CM, Mackey JR, Scarfe AG, Valle JW, McDonald AC, Carter R, Tebbutt NC, Goldstein D, Shannon J, Dervenis C, Glimelius B, Deakin M, Charnley RM, Anthony A, Lerch MM, Mayerle J, Oláh A, Büchler MW, Greenhalf W; European Study Group for Pancreatic Cancer. Intratumoural expression of deoxycytidylate deaminase or ribonucleotide reductase subunit M1 expression are not related to survival in patients with resected pancreatic cancer given adjuvant chemotherapy. *Br J Cancer*. 2018 Apr;118(8):1084-1088.
 23. Bowden DL, Sutton PA, Wall MA, Jithesh PV, Jenkins RE, Palmer DH, Goldring CE, Parsons JL, Park BK, Kitteringham NR, Vimalachandran D. Proteomic profiling of rectal cancer reveals acid ceramidase is implicated in radiation response. *J Proteomics*. 2018

May 15;179:53-60.

24. Elander NO, Aughton K, Ghaneh P, Neoptolemos JP, Palmer DH, Cox TF, Campbell F, Costello E, Halloran CM, Mackey JR, Scarfe AG, Valle JW, McDonald AC, Carter R, Tebbutt NC, Goldstein D, Shannon J, Dervenis C, Glimelius B, Deakin M, Charnley RM, Anthony A, Lerch MM, Mayerle J, Oláh A, Büchler MW, Greenhalf W; European Study Group for Pancreatic Cancer. Expression of dihydropyrimidine dehydrogenase (DPD) and hENT1 predicts survival in pancreatic cancer. *Br J Cancer*. 2018 Apr;118(7):947-954.
25. Fleeman N, Abdulla A, Bagust A, Beale S, Richardson M, Stainthorpe A, Boland A, Kotas E, McEntee J, Palmer D. Pegylated Liposomal Irinotecan Hydrochloride Trihydrate for Treating Pancreatic Cancer After Gemcitabine: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. *Pharmacoeconomics*. 2018 Mar;36(3):289-299.
26. Sutton PA, Jithesh PV, Jones RP, Evans JP, Vimalachandran D, Malik HZ, Park BK, Goldring CE, Palmer DH, Kitteringham NR. Exome sequencing of synchronously resected primary colorectal tumours and colorectal liver metastases to inform oncosurgical management. *Eur J Surg Oncol*. 2018 Jan;44(1):115-121.
27. Ghaneh P, Kleeff J, Halloran CM, Raraty M, Jackson R, Melling J, Jones O, Palmer DH, Cox TF, Smith CJ, O'Reilly DA, Izbicki JR, Scarfe AG, Valle JW, McDonald AC, Carter R, Tebbutt NC, Goldstein D, Padbury R, Shannon J, Dervenis C, Glimelius B, Deakin M, Anthony A, Lerch MM, Mayerle J, Oláh A, Rawcliffe CL, Campbell F, Strobel O, Büchler MW, Neoptolemos JP; European Study Group for Pancreatic Cancer. The Impact of Positive Resection Margins on Survival and Recurrence Following Resection and Adjuvant Chemotherapy for Pancreatic Ductal Adenocarcinoma. *Ann Surg*. 2019 Mar;269(3):520-529.
28. Springfield C, Jäger D, Büchler MW, Strobel O, Hackert T, Palmer DH, Neoptolemos JP. Chemotherapy for pancreatic cancer. *Presse Med*. 2019 Mar;48(3 Pt 2):e159-e174.
29. Primrose JN, Fox RP, Palmer DH, Malik HZ, Prasad R, Mirza D, Anthony A, Corrie P, Falk S, Finch-Jones M, Wasan H, Ross P, Wall L, Wadsley J, Evans JTR, Stocken D, Praseedom R, Ma YT, Davidson B, Neoptolemos JP, Iveson T, Raftery J, Zhu S, Cunningham D, Garden OJ, Stubbs C, Valle JW, Bridgewater J; BILCAP study group. Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study. *Lancet Oncol*. 2019;20(5):663-673.
30. Alabraba E, Joshi H, Bird N, Griffin R, Sturgess R, Stern N, Sieberhagen C, Cross T, Camenzuli A, Davis R, Evans J, O'Grady E, Palmer D, Diaz-Nieto R, Fenwick S, Poston G, Malik H. Increased multimodality treatment options has improved survival for Hepatocellular carcinoma but poor survival for biliary tract cancers remains unchanged. *Eur J Surg Oncol*. 2019 Apr 9. pii: S0748-7983(19)30392-0.
31. Lamarca A, Ross P, Wasan HS, Hubner RA, McNamara MG, Lopes A, Manoharan P, Palmer D, Bridgewater J, Valle JW. Advanced intrahepatic cholangiocarcinoma: post-hoc analysis of the ABC-01, -02 and -03 clinical trials. *J Natl Cancer Inst*. 2019 May 11. pii: djz071.
32. Bird NTE, Manu N, Quinn L, Needham A, Jones R, Fenwick S, Poston G, Palmer D, Malik H. Evaluation of the utility of prognostic models for patients with resected hilar cholangiocarcinoma. *HPB (Oxford)*. 2019 May 8. pii: S1365-182X(19)30099-1.